Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01940679 · ClinicalTrials.gov registry record · NA

Bioavailability of Encapsulated Omega-3 Fatty Acids

A NA study of Bioavailability of Omega-3s in Military Rations, sponsored by United States Army Research Institute of Environmental Medicine.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT01940679: Completed NA study of Bioavailability of Omega-3s in Military Rations, sponsored by United States Army Research Institute of Environmental Medicine.

NCT01940679 is a NA study of Bioavailability of Omega-3s in Military Rations that has completed, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01940679, a NA study of Bioavailability of Omega-3s in Military Rations, has completed, sponsored by United States Army Research Institute of Environmental Medicine.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

Omega-3 fatty acids (n-3s), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have anti-inflammatory properties and other documented beneficial health effects that could warrant n-3 fortification of combat rations. However, military combat rations must meet rigorous shelf-stability guidelines (e.g.,, 3 years at 80°F or 6 months at 100°F), which is problematic for natural food sources of n-3s (e.g., oil and fish), which degrade when exposed to high temperatures and prolonged shelf-storage. Encapsulation, e.g., coating freeze dried n-3s with gelatin, can prevent this degradation, and Natick Soldier Research, Development and Engineering Center's (NSRDEC) Combat Feeding Directorate used encapsulated n-3 technology to produce n-3 enriched ration items that withstand environmental stressors and meet shelf-life specifications for military rations. However, the bioavailability of the encapsulated n-3s in these rations is unknown, particularly when they are incorporated into high-protein food items and exposed to high temperatures and prolonged storage. In this randomized, cross-over study, civilian and/or military personnel will be asked to consume: 1) a high protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 2) a low-protein food item enriched with encapsulated n-3s (600 mg) and previously stored for 6 months at 100°F; 3) a high protein food item with encapsulated n-3s (600 mg) that was not subjected to high-temperature and prolonged storage; and, 4) a low-protein food item with encapsulated n-3s (600 mg) that was not subjected to high temperature and prolonged storage. Serial blood sampling to measure acute changes in the circulating fatty acid profile will occur in the hour before and 6 hours after consumption of each ration component. The only known risks, which this study presents to participants, are those associated with venous catheter placement. The results will help military ration develop

Interventions

  • DIETARY_SUPPLEMENT encapsulated 600 mg EPA/DHA

Study Locations (1)

Massachusetts

  • U.S. Army Research Institute of Environmental Medicine - Natick

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2013-09
Est. Completion 2013-12
Phase NA

What the finished NCT01940679 record still lists

NCT01940679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Bioavailability of Omega-3s in Military Rations appearing as the primary indexed condition, and to 1 intervention - of which encapsulated 600 mg EPA/DHA is the first listed.

NCT01940679 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01940679 about?

NCT01940679 is a clinical study titled "Bioavailability of Encapsulated Omega-3 Fatty Acids". Omega-3 fatty acids (n-3s), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have anti-inflammatory properties and other documented beneficial health effects that could warrant n-3 fortification of combat rations. However, military combat rations must meet rigorous shelf-stab...

What is the current status of trial NCT01940679?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2013-09. Estimated completion is 2013-12.

What conditions does trial NCT01940679 study?

This clinical trial studies the following conditions: Bioavailability of Omega-3s in Military Rations.

What interventions are being tested in trial NCT01940679?

The interventions under investigation include: encapsulated 600 mg EPA/DHA (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01940679?

This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01940679 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01940679's enrollment target sits among peer trials

14 1909th of 2000 higher than 90 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01940679, the US trial registry maintained by the National Library of Medicine. NCT01940679 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.